![Setting Bigger Targets For Next-Gen Vaccines](https://cdn.magzter.com/Bio Spectrum/1719760825/articles/BC2FraUDp1721727735527/Healthcare.jpg)
Experts worldwide are adopting novel research approaches in the molecular design of vaccines, and vaccine technology platforms. India is seeing increasing interdisciplinary research, and a rise in cutting-edge technological interventions in fundamental and translational research. The time is ripe for boosting out-of-the-box R&D approaches in vaccinology. Let's explore further.
The National Institute for Allergy and Infectious Diseases (NIAID), one of the 27 institutes and centres that make up the National Institutes of Health (NIH) of the US, referred to next-generation vaccines as those with enhanced breadth of protection to variants, improved durability, and enhanced ability to block infection/transmission relative to currently approved vaccines. The Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic, describes vaccine technology platforms as technologies that are essential for rapid responses to emerging viral threats.
Essentially, vaccine platform technologies are systems that use the same basic components as a backbone but can be adapted for use against different pathogens by inserting new genetic or protein sequences. Rational vaccine design, developed using suitable vaccine technology platforms, could thus present significant advantages in immunisation.
Creating such an unprecedented disease agnostic vaccine technology platform can empower the world to be ready for future pandemics. Studies have shown that next-generation vaccines can enable a higher spectrum of protection against multiple variants, increased durability, and minimal safety concerns due to side effects while increasing their immunogenicity.
Each vaccine's utility or efficiency is determined by its formulation, adjuvants, and mode of action.
This story is from the July 2024 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the July 2024 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
![Economic Survey Lays Focus On Mental Healthcare For The First Time](https://reseuro.magzter.com/100x125/articles/118/1817025/Q7Sf4hHjt1725367182047/crp_ECONOMIC-SURVEY-LAYS-FOCUS-ON-MENTAL-HEALTHCARE-FOR-THE-FIRST-TIME.jpg)
Economic Survey Lays Focus On Mental Healthcare For The First Time
For the first time ever, the Economic Survey 2023-24 tabled by the Union Minister of Finance and Corporate Affairs Nirmala Sitharaman in Parliament recently, talks extensively about mental health, its significance and implications on policy recommendations.
![IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus](https://reseuro.magzter.com/100x125/articles/118/1817025/eOn7kOXZz1725368478930/IITG-DISCOVERS-RNADESTROYING-FUNCTION-OF-P30-PROTEIN-IN-AFRICAN-SWINE-FEVER-VIRUS.jpg)
IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus
Indian Institute of Technology Guwahati (IIT-G) researchers have investigated the biochemistry of the African Swine Fever Virus (ASFV) protein, focusing on understanding the biochemical processes of infection to devise effective control strategies.
![13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors](https://reseuro.magzter.com/100x125/articles/118/1817025/bDcllpvRO1725368308460/13TH-BENGALURU-INDIA-NANO-2024-BRINGS-TOGETHER-1018-DELEGATES-3000-VISITORS.jpg)
13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors
The 13th edition of Bengaluru INDIA NANO 2024, organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS), and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) concluded on August 3 with participation of 1018 delegates, 11 countries including Korea, Morocco, USA, UK, France, Canada, Germany, Netherlands, Russia, Japan, and Poland, 49 exhibitors comprising 21 startups and 28 industry and institutes, and 200 posters. The exhibition had a footfall of 3,000+ visitors.
![Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle](https://reseuro.magzter.com/100x125/articles/118/1817025/JGFkC4RuJ1725367789393/ARE-NUTRACEUTICALS-DRUGS-EXAMINING-A-NEEDLESS-REGULATORY-TUSSLE.jpg)
Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle
The news has been around for a while which has put a big question mark ahead of the Indian nutraceuticals industry.
![Can India Reclaim API Throne from China?](https://reseuro.magzter.com/100x125/articles/118/1817025/mH-I2SrnN1725367482092/CAN-INDIA-RECLAIM-API-THRONE-FROM-CHINA.jpg)
Can India Reclaim API Throne from China?
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).
![JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana](https://reseuro.magzter.com/100x125/articles/118/1817025/HSywtyQ251725367390797/JRS-PHARMA-GUJARAT-MICROWAX-OPEN-NEW-MANUFACTURING-FACILITY-IN-MEHSANA.jpg)
JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana
JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax, has commissioned a new manufacturing facility for cotton-based croscarmellose sodium.
![NovaLead's patented repurposed drug for treating DFU gets CDSCO approval](https://reseuro.magzter.com/100x125/articles/118/1817025/17z8NoZhx1725367355909/NOVALEADS-PATENTED-REPURPOSED-DRUG-FOR-TREATING-DFU-GETS-CDSCO-APPROVAL.jpg)
NovaLead's patented repurposed drug for treating DFU gets CDSCO approval
Pune-based NovaLead Pharma has announced that the drug regulator in India, Central Drugs Standard Control Organisation (CDSCO), has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.
![Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda](https://reseuro.magzter.com/100x125/articles/118/1817025/Knuz1eETb1725367328230/MEDICAMEN-ORGANICS-EXPANDS-FOOTPRINT-IN-EAST-AFRICA-WITH-75000-INVESTMENT-IN-RWANDA.jpg)
Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda
Delhi-based pharma company Medicamen Organics has taken a significant step in its global expansion strategy by signing a Memorandum of Understanding (MoU) with Depot Pharmacy Yego in Rwanda.
![Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr](https://reseuro.magzter.com/100x125/articles/118/1817025/-zI80qZv51725367272206/MANKIND-PHARMA-ACQUIRES-100-STAKE-IN-BHARAT-SERUMS-AND-VACCINES-FOR-RS-13630-CR.jpg)
Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr
Mankind Pharma has entered into a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines Limited (BSV) from Advent International, for an enterprise value of approx.
![Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence](https://reseuro.magzter.com/100x125/articles/118/1817025/N7D5ta94z1725367231775/THYROCARE-BUYS-POLO-LABS-PATHOLOGY-DIAGNOSTIC-BIZ-TO-STRENGTHEN-NORTHERN-INDIA-PRESENCE.jpg)
Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence
Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business.